Polskie Archiwum Medycyny Wewnętrznej
-
Pol. Arch. Med. Wewn. · Dec 2023
Prevalence and assessment of risk factors among Polish adults with post-COVID syndrome: 12-month follow-up study.
Previous studies have indicated that COVID-19 symptoms may persist for up to 12 months after recovery; however, data on this phenomenon are still limited. ⋯ After 12 months, persistent symptoms were declared by 65.7% of the patients. The most common symptoms 3 and 12 months after the infection were worse tolerance to exercise, fatigue, palpitations, and memory or concentration problems. Women are at a higher risk of experiencing persistent symptoms, and COVID-19 severity was a predictor of persistent post-COVID-19 symptoms.
-
Pol. Arch. Med. Wewn. · Dec 2023
Randomized Controlled TrialThe diuretic, natriuretic and chloride-regaining effects of oral acetazolamide as an add-on therapy for acute heart failure with volume overload. A single center, prospective, randomized study.
Decongestion is a therapeutic target in acute heart failure (AHF). Acetazolamide is a diuretic that decreases proximal tubular sodium reabsorption, and may also reverse hypochloremia Objectives: We assessed the decongestive, natriuretic, and chloride‑regaining effects as well as the renal safety profile of oral acetazolamide (250 mg) used as an add‑on therapy in patients with AHF. ⋯ Oral acetazolamide seems to be a valuable add‑on therapy that helps achieve comprehensive decongestion in patients with AHF.
-
Pol. Arch. Med. Wewn. · Dec 2023
Heart failure with reduced, mildly reduced and preserved ejection fraction: outcomes and predictors of prognosis.
Recently, a stratification of the heart failure (HF) phenotypes, which classifies HF into 3 subtypes based on ejection fraction, has been introduced. Before that, clinical trials and registries have been mainly devoted to HF with reduced ejection fraction (HFrEF). As a result, data on long‑term survival trends for individual HF phenotypes are scarce. ⋯ Survival in HFrEF is worse as compared with HFmrEF and HFpEF, where it is similar. The HF phenotypes differ in most of the parameters that affect survival.
-
Pol. Arch. Med. Wewn. · Dec 2023
Permanent single chamber atrial pacing: obsolete or a viable alternative to dual-chamber in selected patients with sinus node disease?
Single atrial stimulation (AAI) has been commonly used for permanent pacing in sick sinus syndrome and significant bradycardia. ⋯ The reliability of AAI pacing decreases with each year of observation due to development of AF and AVB. However, in the current era of effective AF treatment, the advantages of AAI pacemakers, such as lower incidence of lead malfunction, venous occlusion, and infection, as compared with dual-chamber pacemakers, may make AAI pacemakers a viable option.